Pulmonx Co. (NASDAQ:LUNG) CEO Sells $197,699.46 in Stock

Pulmonx Co. (NASDAQ:LUNG) CEO Steven S. Williamson sold 27,689 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $7.14, for a total value of $197,699.46. Following the completion of the sale, the chief executive officer now directly owns 194,342 shares in the company, valued at approximately $1,387,601.88. The trade was a 12.47 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Pulmonx Stock Down 5.5 %

Shares of NASDAQ LUNG opened at $8.19 on Thursday. The firm has a market cap of $325.93 million, a P/E ratio of -5.69 and a beta of 0.50. The firm’s 50 day moving average price is $6.93 and its 200 day moving average price is $6.93. Pulmonx Co. has a 1 year low of $5.46 and a 1 year high of $10.01. The company has a debt-to-equity ratio of 0.40, a quick ratio of 6.77 and a current ratio of 7.70.

Pulmonx (NASDAQ:LUNG) last announced its quarterly earnings results on Wednesday, February 19th. The company reported ($0.33) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.12. The company had revenue of $23.77 million for the quarter, compared to analyst estimates of $22.29 million. Pulmonx had a negative net margin of 67.31% and a negative return on equity of 55.36%. As a group, sell-side analysts anticipate that Pulmonx Co. will post -1.55 earnings per share for the current year.

Analysts Set New Price Targets

LUNG has been the topic of a number of recent research reports. Citigroup reaffirmed a “neutral” rating and set a $7.50 price objective (down previously from $17.00) on shares of Pulmonx in a research report on Wednesday, December 11th. Wells Fargo & Company cut their price objective on Pulmonx from $10.00 to $8.00 and set an “equal weight” rating on the stock in a research report on Wednesday, December 11th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $12.75.

Hedge Funds Weigh In On Pulmonx

Hedge funds and other institutional investors have recently made changes to their positions in the business. 272 Capital LP acquired a new position in shares of Pulmonx during the 3rd quarter valued at $25,000. BNP Paribas Financial Markets acquired a new position in shares of Pulmonx during the 4th quarter valued at $43,000. R Squared Ltd acquired a new position in shares of Pulmonx during the 4th quarter valued at $46,000. ProShare Advisors LLC acquired a new position in shares of Pulmonx during the 4th quarter valued at $72,000. Finally, Stifel Financial Corp acquired a new position in shares of Pulmonx during the 4th quarter valued at $81,000. Institutional investors and hedge funds own 91.04% of the company’s stock.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.